Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OrienX 010

Drug Profile

OrienX 010

Alternative Names: OrienX010; OrienX10; Recombinant hGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; Recombinant hGM-CSF HSV - OrienGene Biotechnology; rhGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; rhGM-CSF HSV - OrienGene Biotechnology

Latest Information Update: 11 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OrienGene Biotechnology
  • Developer Beijing Bozhiyin T&S; OrienGene Biotechnology; START Shanghai
  • Class Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • No development reported Solid tumours

Most Recent Events

  • 02 Jun 2023 Adverse events and efficacy data from a phase-I trial in Malignant melanoma presented at the presented at 59th Annual Meeting of American Society of Clinical Oncology (ASCO-2023)
  • 09 Sep 2022 Efficacy and adverse events data from a phase I trial in Malignant melanoma presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (Intratumoural, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top